Skip to content

3 Phosphoglycerate Dehydrogenase Deficiency C0580190

Published: July 22, 2026Updated: August 27, 2026

A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Intractable seizures

Recurrent seizures that are difficult to control with standard anti-epileptic medications, often beginning in infancy.

Seek immediate emergency care for any seizure lasting more than 5 minutes or if seizures occur in clusters.

!

Progressive encephalopathy

Worsening neurologic function over time with increasing severity of symptoms if untreated.

Seek urgent neurologic evaluation if there is sudden worsening of seizures, consciousness, or motor function.

Severe developmental delay

(neurologic)

Significant delays in motor skills, speech, and cognitive development due to impaired serine synthesis affecting brain development.

Frequency: 90-100% of patients

Severe microcephaly

(constitutional)

Abnormally small head circumference present at birth or developing shortly after, indicating impaired brain growth.

Frequency: 85-95% of patients

Profound hypotonia

(neurologic)

Severely reduced muscle tone present from birth, leading to poor head control and delayed motor milestones.

Frequency: 75-85% of patients

Failure to thrive

(constitutional)

Inadequate weight gain and growth in infancy due to metabolic demands and feeding difficulties.

Frequency: 60-70% of patients

Feeding difficulties

(gastrointestinal)

Poor suck reflex and difficulty feeding, often requiring feeding assistance or tube feeding.

Frequency: 50-65% of patients

Cortical visual impairment

(neurologic)

Vision problems due to abnormal development of the visual cortex, not due to eye abnormalities.

Frequency: 40-55% of patients

Eczematous skin lesions

(dermatologic)

Dry, itchy, inflamed skin patches that may resemble eczema, possibly related to altered serine metabolism affecting skin integrity.

Frequency: 20-30% of patients

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combination drug regimen with regular assessment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Serine Supplementation

Serine amino acid supplementation is a cornerstone of treatment for 3-phosphoglycerate dehydrogenase deficiency, a rare metabolic disorder affecting serine biosynthesis. Dosage is individualized based on metabolic testing and clinical response, typically starting at lower amounts and gradually increasing.

dietary
3

Glycine Supplementation

Glycine is often administered alongside serine as both amino acids are interconnected in the metabolic pathway. Combined supplementation may provide additional neurological benefits and improve overall amino acid balance in patients with this serine synthesis disorder.

dietary

Additional treatment options

Anticonvulsant Medications

Seizure management is critical for patients presenting with epilepsy secondary to 3-PGDH deficiency. Anticonvulsant therapy is tailored to seizure type and severity, with regular monitoring of therapeutic levels and potential drug interactions.

medication

Neurodevelopmental Physical Therapy

Physical therapy focuses on improving motor coordination, muscle tone abnormalities, and developmental delays commonly associated with this metabolic condition. Sessions are designed to be engaging and functional for the patient's age and abilities.

physical_therapy

Metabolic and Neurological Monitoring

Regular monitoring of amino acid levels, growth parameters, and neurological development is essential. This includes periodic plasma and CSF amino acid analysis, developmental assessments, and neuroimaging as clinically indicated to track disease progression.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is 3 Phosphoglycerate Dehydrogenase Deficiency C0580190?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

de Koning TJ, Klomp LW. Serine biosynthesis and its importance in health and disease. J Inherit Metab Dis. 2004;27(3):307-318.

review2004View source →
2

Hart CE, Race V, Achouri Y, et al. Phosphoglycerate dehydrogenase deficiency and serine deficiency: diagnostic and therapeutic approaches. Mol Genet Metab. 2007;92(1-2):9-15.

review2007View source →
3

de Koning TJ, Snell K, Duran M, et al. L-serine in disease and development. Biochem Soc Trans. 2003;31(Pt 6):1405-1408.

clinical_trial2003View source →
4

Online Mendelian Inheritance in Man. Phosphoglycerate dehydrogenase deficiency. OMIM #601291.

5

Spaapen LJ, Rubio-Gozalbo ME. Serine deficiency disorders. J Inherit Metab Dis. 2003;26(4):309-318.

review2003View source →
6

Fischer J, Carmi R. Defects in serine biosynthesis. In: Saudubray JM, Baumgartner MR, Walter J, eds. Inborn Metabolic Diseases: Diagnosis and Treatment. 6th ed. Springer; 2016:321-328.

textbook2016View source →
7

American College of Medical Genetics and Genomics. Newborn screening: toward a uniform screening panel and system. Genet Med. 2006;8(Suppl 1):1S-252S.

position_statement2006View source →
8

El-Hattab AW. Serine biosynthesis and its disorders. In: Adam MP, Everman DB, Mirzaa GM, et al., eds. GeneReviews. University of Washington; 2016.

review2016View source →
9

Matsumoto M, Hakoshima M, Serine deficiency disorders: clinical phenotypes and molecular mechanisms. J Neurol Sci. 2019;407:116527.

meta_analysis2019View source →
10

European Reference Network for Rare Hereditary Metabolic Disorders. Consensus guidelines for the diagnosis and management of serine biosynthesis disorders. Orphanet J Rare Dis. 2021;16(1):127.

consensus2021View source →

Medication Comparisons

Compare medications used to treat 3 Phosphoglycerate Dehydrogenase Deficiency C0580190. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy